Exelixis Inc - Company Profile
Powered by
All the data and insights you need on Exelixis Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Exelixis Inc Strategy Report
- Understand Exelixis Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Exelixis Inc patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
AU2021200202B2 | Grant | CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE | A61K31/397; A61K31/4427; A61K31/445; A61K31/4523; A61P35/00; A61P35/02; C07B2200/13; C07D401/04 | September 08, 2022 |
US11433064B2 | Grant | Methods of using c-Met modulators | A61K2121/00; A61K2300/00; A61K31/015; A61K31/4188; A61K31/47; A61K31/4706; A61K31/495; A61K31/517; A61K41/00; A61K45/06; A61N5/10; A61P35/00; A61P43/00; C07D215/22; | September 06, 2022 |
AU2021226747A1 | Application | Compounds and methods of use | A61P35/00; C07D401/14; C07D405/14; C07D471/04 | September 01, 2022 |
IL295052A | Application | Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone | A61K31/397; A61K31/4427; A61K31/445; A61K31/4523; A61P35/00; A61P35/02; C07B2200/13; C07D401/04 | September 01, 2022 |
RS52754B2 | Grant | MALATE SALT OF N- (4-{ [6,7-BIS (METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL-N'- (4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER | A61K31/47; A61P25/00; A61P35/00; A61P43/00; A61P5/14; C07B2200/13; C07D215/22; C07D215/233; C07D417/14 | August 31, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer